Tom 15, Nr 1 (2020)
NIEWYDOLNOŚĆ SERCA
Opublikowany online: 2020-06-30
Wyświetlenia strony
585
Wyświetlenia/pobrania artykułu
150
Potencjał prozakrzepowy pacjentów z zaostrzeniem przewlekłej niewydolności serca bez współistniejącego migotania przedsionków. Aktualny stan wiedzy i potencjalne implikacje kliniczne.
Kardiol Inwazyjna 2020;15(1):28-32.
Streszczenie
Wraz z narastającą liczbą pacjentów cierpiących na przewlekłą niewydolność serca (HF), coraz istotniejszym zagadnieniem staje się zapobieganie niekorzystnym następstwom HF. W ostatnich latach wykazano zwiększone ryzyko zakrzepowo-zatorowe, w tym ryzyko udaru niedokrwiennego mózgu również u pacjentów z HF bez migotania przedsionków. Jak udowodniono w przebiegu przewlekłej HF dochodzi do zaburzenia każdej składowej triady Virchowa. W tym opracowaniu zostaną przedstawione patofizjologiczne mechanizmy nadkrzepliwości w HF, dostępne badania dotyczące ryzyka zdarzeń zakrzepowo-zatorowych oraz ich możliwej profilaktyki. Rozważymy również potencjalne nowe modele oceny ryzyka wśród tych pacjentów.
Słowa kluczowe: niewydolność sercarytm zatokowyudar niedokrwienny mózguleczenie przeciwzakrzepoweprofilaktyka
Referencje
- Roger VL. Epidemiology of heart failure. Circ Res. 2013; 113(6): 646–659.
- Nowak K, Stępień K, Furczyńska P, et al. The awareness and knowledge about heart failure in Poland - lessons from the Heart Failure Awareness Day and internet surveys. Folia Med Cracov. 2019; 59(2): 93–109.
- Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119(14): e391–e479.
- Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Abdul-Rahim AH, Perez AC, Fulton RL, et al. Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), GISSI-Heart Failure (GISSI-HF) Committees and Investigators. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. Circulation. 2015; 131(17): 1486–1494.
- Adelborg K, Szépligeti S, Sundbøll J, et al. Risk of Stroke in Patients With Heart Failure: A Population-Based 30-Year Cohort Study. Stroke. 2017; 48(5): 1161–1168.
- Alikhan R, Cohen AT, Combe S, et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004; 164(9): 963–968.
- Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol. 2001; 54(8): 810–816.
- Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology. 2000; 54(2): 288–294.
- Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999; 33(5): 1424–1426.
- Shantsila E, Wrigley BJ, Blann AD, et al. A contemporary view on endothelial function in heart failure. Eur J Heart Fail. 2012; 14(8): 873–881.
- Klosinska M, Rudzinski T, Grzelak P, et al. Endothelium-dependent and -independent vasodilation is more attenuated in ischaemic than in non-ischaemic heart failure. Eur J Heart Fail. 2009; 11(8): 765–770.
- Comini L, Bachetti T, Gaia G, et al. Aorta and skeletal muscle NO synthase expression in experimental heart failure. J Mol Cell Cardiol. 1996; 28(11): 2241–2248.
- Flierl U, Fraccarollo D, Widder JD, et al. Endothelial dysfunction in heart failure. Pharmacol Rep. 2008; 60(1): 119–126.
- Chong AY, Lip GYH. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail. 2007; 9(2): 124–128.
- Berger JS, Peterson E, LalibertÉ F, et al. Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. J Card Fail. 2019; 25(6): 436–447.
- Kang SH, Kim J, Park JJ, et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol. 2017; 248: 182–187.
- Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
- Beggs SAS, Rørth R, Gardner RS, et al. Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart. 2019; 105(17): 1325–1334.
- Coulis AA, Mackey WC. A Review of the Efficacy and Safety Profiles of the Novel Oral Anticoagulants in the Treatment and Prevention of Venous Thromboembolism. Clin Ther. 2018; 40(12): 2140–2167.
- Stepien K, Nowak K, Zalewski J, et al. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. Vascul Pharmacol. 2019; 120: 106567.
- Stępień K, Nowak K, Zalewski J, et al. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and colorectal cancer: a single‑center experience. Kardiol Pol. 2019; 77(12): 1186–1189.
- Zannad F, Anker SD, Byra WM. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018; 379(14): 1332–1342.
- Greenberg B, Neaton JD, Anker SD, et al. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. JAMA Cardiol. 2019; 4(6): 515–523.
- Melgaard L, Gorst-Rasmussen A, Lane DA, et al. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA. 2015; 314(10): 1030–1038.
- Lip GYH, Piotrponikowski P, Andreotti F, et al. Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost. 2012; 108(6): 1009–1022.
- Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost. 2014; 112(1): 32–42.
- Undas A, Slowik A, Wolkow P, et al. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res. 2010; 125(4): 357–361.
- Kremers RMW, Peters TC, Wagenvoord RJ, et al. The balance of pro- and anticoagulant processes underlying thrombin generation. J Thromb Haemost. 2015; 13(3): 437–447.
- Carcaillon L, Alhenc-Gelas M, Bejot Y, et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol. 2011; 31(6): 1445–1451.
- Palka I, Nessler J, Nessler B, et al. Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism. Heart. 2010; 96(14): 1114–1118.
- Popovic B, Zannad F, Louis H, et al. Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure. Int J Cardiol. 2019; 274: 195–201.
